Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

70
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
70

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial.

Blood·2026
Same author

IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLL.

HemaSphere·2026
Same author

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation.

HemaSphere·2026
Same author

Chronic lymphocytic leukemia with <i>IGH</i>::<i>BCL3</i>-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscape.

HemaSphere·2026
Same author

The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemia.

Leukemia·2026
Same author

Transition Into Clinical Routine and Survival Outcomes of BCL2- and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry.

European journal of haematology·2026

Related Experiment Video

Updated: Mar 11, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K

Targeted Therapy of CLL.

Othman Al-Sawaf1, Kirsten Fischer, Barbara Eichhorst

  • 1Department I of Internal Medicine, German CLL Study Group, Center for Integrated Oncology Cologne-Bonn, University Hospital of Cologne, Cologne, Germany.

Oncology Research and Treatment
|November 28, 2016
PubMed
Summary

Targeted therapies, including kinase inhibitors and Bcl-2 inhibitors, have transformed chronic lymphocytic leukemia (CLL) treatment. This review covers current agents and future challenges in CLL therapy.

More Related Videos

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.2K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K

Related Experiment Videos

Last Updated: Mar 11, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

22.6K
A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.2K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.1K

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic lymphocytic leukemia (CLL) treatment has evolved with targeted therapies.
  • The B cell receptor signaling pathway is crucial in CLL pathogenesis.
  • High Bcl-2 expression in CLL drives anti-apoptosis.

Purpose of the Study:

  • To review current targeted agents for CLL.
  • To summarize preclinical and clinical data.
  • To discuss future challenges in CLL targeted therapy.

Main Methods:

  • Review of preclinical and clinical data.
  • Analysis of targeted agents including CD20 antibodies, kinase inhibitors, and Bcl-2 inhibitors.
  • Discussion of therapeutic outcomes and challenges.

Main Results:

  • CD20 antibodies improve outcomes with chemotherapy.
  • Ibrutinib and idelalisib target the B cell receptor pathway.
  • Venetoclax, a Bcl-2 inhibitor, shows high efficacy in CLL.

Conclusions:

  • Targeted therapies have significantly advanced CLL treatment.
  • Kinase inhibitors and Bcl-2 inhibitors are key therapeutic options.
  • Ongoing research addresses future challenges in CLL targeted therapy.